MK 2866 - Dragon Pharma

Ostarine commonly known as "Enobosarm" or "MK-2866", is a Selective Androgen Receptor Modulator (SARM) first described in 2001 by The University of Tennessee Research Corporation. Its electively targets androgen receptors in muscle and bone tissues, promoting muscle growth and fat loss without the strong androgenic side effects of anabolic steroids. Shortly after, GTx Inc. developed it, initially partnering with Merck in 2007 for further research.  Gained popularity in the fitness community for improving muscle retention during cutting phases and has been studied for treating cancer-related muscle wasting, although Phase III trials faced setbacks in 2013.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about MK 2866 by Dragon Pharma, consult with your doctor or healthcare professional.